Incyte Published Results of Opzelura (ruxolitinib) in P-III (TRuE-V) Clinical Trial Program for Vitiligo in the NEJM
Shots:
- The (TRuE-V) clinical trial program includes 2 P-III studies i.e., (TRuE-V1 & V2) evaluating ruxolitinib (1.5%) vs vehicle in 300 patients aged ≥12yrs. with vitiligo
- The results showed facial & total body repigmentation, and greater proportions of patients reached F-VASI & T-VASI @24wk. with a higher proportion of patients responding at 521wk., ~30% vs ~13% achieved ≥75% improvement from baseline in F-VASI (F-VASI75) @24wk.; 50% achieved F-VASI75 @52wk.
- ≥15% vs ~2% achieved ≥90% improvement from baseline in F-VASI (F-VASI90) @24wk.; 30% achieved F-VASI90 @52wk., ≥50% improvement in T-VASI (T-VASI50) @52wk., an improvement on percentage change from baseline in F-BSA. The MAA for ruxolitinib is under the EMA’s review for the same indication
Ref: Buisnesswire | Image: Incyte
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
